Prevention of cardiovascular disease in rheumatoid arthritis

Autoimmunity Reviews

Volumn 14, Issue 10, 2015, Pages 952-969

  Hollan, I ^a   Dessein, P H ^b   Ronda, N ^c   Wasko, M C ^e   Svenungsson, E ^d   Agewall, S ^f,l   Cohen Tervaert, J W ^g   Maki Petaja, K ^h   Grundtvig, M ⁱ   Karpouzas, G A ^j,m   Meroni, P L ^k,n  

^a Hospital for Rheumatic Diseases   (Norway)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF PARMA   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ INNLANDET HOSPITAL TRUST   (Norway)

^j HARBOR UCLA MEDICAL CENTER   (United States)

^k UNIVERSITY OF MILAN   (Italy)

^l UNIVERSITY OF OSLO   (Norway)

^m Los Angeles Biomedical Research Institute   (United States)

ⁿ ISTITUTO AUXOLOGICO ITALIANO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; VITAMIN D; ANTIRHEUMATIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BODY COMPOSITION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL PROGENITOR CELL; GLUCOSE METABOLISM; HEART PROTECTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPERURICEMIA; HYPOTHYROIDISM; INFLAMMATION; INFLUENZA; INTESTINE FLORA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MENTAL STRESS; MOUTH HYGIENE; OBESITY; PERIODONTITIS; PHYSICAL ACTIVITY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SLEEP DISORDERED BREATHING; SMOKING; SOCIAL PSYCHOLOGY; THROMBOPHILIA; UNDERWEIGHT; VITAMIN BLOOD LEVEL; WAIST CIRCUMFERENCE; ANIMAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; MORBIDITY; RISK FACTOR;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; MORBIDITY; RISK FACTORS; SMOKING;

EID: 84940614497     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.06.004     Document Type: Review

References (257)

1. Skeoch S., Bruce I.N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nat Rev Rheumatol 2015.
2. Hollan I. Vascular inflammation in systemic rheumatic diseases. Curr Med Lit Rheumatol 2011, 30:33-45.
3. Crowson C.S., Liao K.P., Davis J.M., Solomon D.H., Matteson E.L., Knutson K.L., et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013, 166:622-628.
4. Hollan I., Meroni P.L., Ahearn J.M., Tervaert J.W., Curran S., Goodyear C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12(10):1004-1015.
5. Semb A.G., Rollefstad S., van R.P., Kitas G.D., Matteson E.L., Gabriel S.E. Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Ann Rheum Dis 2014, 73(7):1284-1288.
6. Beinsberger J., Heemskerk J.W., Cosemans J.M. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum 2014, 44(3):345-352.
7. Amaya-Amaya J., Sarmiento-Monroy J.C., Mantilla R.D., Pineda-Tamayo R., Rojas-Villarraga A., Anaya J.M. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res 2013, 56:267-286.
8. Maradit-Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52:402-411.
9. Kitas G.D., Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:607-613.
10. Karpouzas G.A., Malpeso J., Choi T.Y., Li D., Munoz S., Budoff M.J. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014, 73(10):1797-1804.
11. Semb A.G., Rollefstad S., Provan S.A., Kvien T.K., Stranden E., Olsen I.C., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013, 40:359-368.
12. van den Oever I.A., Sattar N., Nurmohamed M.T. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 2014, 73:954-957.
13. Aubry M.C., Maradit-Kremers H., Reinalda M.S., Crowson C.S., Edwards W.D., Gabriel S.E. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007, 34:937-942.
14. McCoy S.S., Crowson C.S., Maradit-Kremers H., Therneau T.M., Roger V.L., Matteson E.L., et al. Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. J Rheumatol 2013, 40:605-610.
15. Sodergren A., Stegmayr B., Lundberg V., Ohman M.L., Wallberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007, 66:263-266.
16. Ben-Zvi I., Goldenberg I., Matetzky S., Grossman C., Elis A., Gavrielov-Yusim N., et al. The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. Clin Rheumatol 2014.
17. Douglas K.M., Pace A.V., Treharne G.J., Saratzis A., Nightingale P., Erb N., et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006, 65:348-353.
18. Peters M.J., Nurmohamed M.T. Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?. Arthritis Res Ther 2013, 15:111.
19. Dessein P.H., Semb A.G. Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?. Ann Rheum Dis 2013, 72:1743-1746.
20. Akkara Veetil B.M., Myasoedova E., Matteson E.L., Gabriel S.E., Crowson C.S. Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 2013, 40:1082-1088.
21. Bartels C.M., Kind A.J., Thorpe C.T., Everett C.M., Cook R.J., McBride P.E., et al. Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. Semin Arthritis Rheum 2012, 42:9-16.
22. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H., Sattar N., Smith J.P., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.
23. Panoulas V.F., Metsios G.S., Pace A.V., John H., Treharne G.J., Banks M.J., et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1286-1298.
24. Bartels C.M., Johnson H., Voelker K., Thorpe C., McBride P., Jacobs E.A., et al. Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care. Arthritis Care Res 2014, 66:1281-1288.
25. Holdaas H., Fellstrom B., Jardine A.G., Nyberg G., Gronhagen-Riska C., Madsen S., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005, 20:974-980.
26. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
27. Semb A.G., Kvien T.K., DeMicco D.A., Fayyad R., Wun C.C., LaRosa J.C., et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012, 64:2836-2846.
28. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
29. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 pt B):2889-2934.
30. Nasjonale Retningslinjer for individuell primærforebygging av hjerte-og karsykdommer 2009.
31. Type 2 diabetes: national clinical guideline for management in primary and secondary care (Update) 2008.
32. Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
33. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012, 19:585-667.
34. Crowson C.S., Gabriel S.E. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011, 70:719-721.
35. Solomon D.H., Reed G., Kremer J.M., Curtis J.R., Farkouh M.E., Harrold L.R., et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015, 67(6):1449-1455.
36. Liao K.P., Cai T., Gainer V.S., Cagan A., Murphy S.N., Liu C., et al. Lipid and lipoprotein levels and trends in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken) 2013, 65(12):2046-2050.
37. Crowson C.S., Matteson E.L., Roger V.L., Therneau T.M., Gabriel S.E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110:420-424.
38. Gonzalez A., Maradit K.H., Crowson C.S., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008, 67:64-69.
39. Rosales-Alexander J.L., Salvatierra J., Llorca J., Magro-Checa C., Gonzalez-Gay M.A., Cantero-Hinojosa J., et al. Cardiovascular risk assessment in rheumatoid arthritis: impact of the EULAR recommendations on a national calibrated score risk index. Clin Exp Rheumatol 2014, 32:237-242.
40. Kawai V.K., Chung C.P., Solus J.F., Oeser A., Raggi P., Stein C.M. The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. Arthritis Rheumatol 2015, 67:381-385.
41. Corrales A., Dessein P.H., Tsang L., Pina T., Blanco R., Gonzalez-Juanatey C., et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther 2015, 17.
42. Corrales A., Gonzalez-Juanatey C., Peiro M.E., Blanco R., Llorca J., Gonzalez-Gay M.A. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014, 73:722-727.
43. Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015, 10:e0117952.
44. Del Rincon I., Polak J.F., O'Leary D.H., Battafarano D.F., Erikson J.M., Restrepo J.F., et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 2015, 74:1118-1123.
45. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., Minhas R., Sheikh A., et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008, 336:1475-1482.
46. Arts E.E., Popa C., Den Broeder A.A., Semb A.G., Toms T., Kitas G.D., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015, 74:668-674.
47. Guidelines for cardiovascular primary prevention in patients with inflammatory rheumatic disease 2011 2011.
48. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
49. Pereira I.A., Mota L.M., Cruz B.A., Brenol C.V., Fronza L.S., Bertolo M.B., et al. 2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol 2012, 52:474-495.
50. Myasoedova E., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010, 22:342-347.
51. Gonzalez-Gay M.A., Gonzalez-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014, 73:1281-1283.
52. Karpouzas G.A., Malpeso J., Choi T.Y., Nightingale P., Kitas G. Differential performance of various cardiovascular risk calculators in predicting surrogate coronary outcomes in rheumatoid arthritis. Ann Rheum Dis 2013, 72.
53. Holmqvist M.E., Wedren S., Jacobsson L.T., Klareskog L., Nyberg F., Rantapaa-Dahlqvist S., et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010, 268:578-585.
54. Nurmohamed M.T. EULAR recommendation update on cardiovascular disease in RA. Ann Rheum Dis 2015, 74:9.
55. Dessein P.H., Corrales A., Lopez-Mejias R., Solomon A., Woodiwiss A.J., Llorca J., et al. The Framingham Score is a useful surrogate marker of high risk subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2015, 74:453.
56. Genest J., McPherson R., Frohlich J., Anderson T., Campbell N., Carpentier A., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
57. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
58. http://www.uptodate.com.
59. Ridker P.M. LDL cholesterol: controversies and future therapeutic directions. Lancet 2014, 384:607-617.
60. Myasoedova E., Crowson C.S., Kremers H.M., Roger V.L., Fitz-Gibbon P.D., Therneau T.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70:482-487.
61. Robertson J., Peters M.J., McInnes I.B., Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013, 9:513-523.
62. Carpentier Y.A., Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 2002, 5:153-158.
63. Montecucco F., Favari E., Norata G.D., Ronda N., Nofer J.R., Vuilleumier N. Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Handb Exp Pharmacol 2015, 224:455-482.
64. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006, 54:2541-2549.
65. Ronda N., Favari E., Borghi M.O., Ingegnoli F., Gerosa M., Chighizola C., et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2014, 73:609-615.
66. Ronda N., Greco D., Adorni M.P., Zimetti F., Favari E., Hjeltnes G., et al. New anti-atherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015, 67(5):1155-1164.
67. Innala L., Moller B., Ljung L., Magnusson S., Smedby T., Sodergren A., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011, 13:R131.
68. Sheng X., Murphy M.J., Macdonald T.M., Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012, 39:32-40.
69. Cojocaru L., Rusali A.C., Suta C., Radulescu A.M., Suta M., Craiu E. The role of simvastatin in the therapeutic approach of rheumatoid arthritis. Autoimmune Dis 2013, 2013:326258.
70. Myasoedova E., Gabriel S.E., Green A.B., Matteson E.L., Crowson C.S. Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study. Arthritis Care Res 2013, 65:1592-1599.
71. El-Barbary A.M., Hussein M.S., Rageh E.M., Hamouda H.E., Wagih A.A., Ismail R.G. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011, 38:229-235.
72. Maki-Petaja K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., McEniery C.M., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007, 50:852-858.
73. Paraskevas K.I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008, 27:281-287.
74. Rollefstad S., Ikdahl E., Hisdal J., Olsen I.C., Smerud K.T., Kitas G., et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases. Ann Rheum Dis 2014, 73.
75. Danninger K., Hoppe U.C., Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?. Int J Rheum Dis 2014, 17(6):606-611.
76. Violi F., Calvieri C., Ferro D., Pignatelli P. Statins as antithrombotic drugs. Circulation 2013, 127:251-257.
77. Mihos C.G., Artola R.T., Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012, 32:287-294.
78. de Jong H.J., Klungel O.H., van D.L., Vandebriel R.J., Leufkens H.G., van der Laan J.W., et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012, 71:648-654.
79. de Jong H.J., Saldi S.R., Klungel O.H., Vandebriel R.J., Souverein P.C., Meyboom R.H., et al. Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One 2012, 7:e41289.
80. de Jong H.J., Tervaert J.W., Saldi S.R., Vandebriel R.J., Souverein P.C., Meyboom R.H., et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011, 41:373-381.
81. Semb A.G., Holme I., Kvien T.K., Pedersen T.R. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011, 50:324-329.
82. Buettner C., Rippberger M.J., Smith J.K., Leveille S.G., Davis R.B., Mittleman M.A. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012, 125:176-182.
83. Toms T.E., Smith J.P., Panoulas V.F., Douglas K.M., Saratzis A.N., Kitas G.D. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients. Musculoskeletal care 2010, 8:2-9.
84. Rollefstad S., Kvien T.K., Holme I., Eirheim A.S., Pedersen T.R., Semb A.G. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis 2013, 72:1968-1974.
85. Xiao Y., Liang L., Pan Y., Lian F., Li L., Lin H., et al. Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA. Rheumatol Int 2013, 33:389-399.
86. McCarey D.W., Sattar N., Hampson R., Madhok R., Capell H., McInnes I.B. A randomised, placebo controlled trial comparing the anti-inflammatory and vascular risk modulatory effects of atorvastatin in rheumatoid arthritis (RA). Arthritis Rheum 2003, 48.
87. Lv S., Liu Y., Zou Z., Li F., Zhao S., Shi R., et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2015, 33(1):69-76.
88. Gottschalk O., Dao Trong M., Metz P., Wallmichrath J., Piltz S., Jauch K., et al. Simvastatin reduces leucocyte- and platelet-endothelial cell interaction in murine antigen-induced arthritis in vivo. Scand J Rheumatol 2014, 43:356-363.
89. Jick S.S., Choi H., Li L., McInnes I.B., Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009, 68:546-551.
90. Stroes E.S., Thompson P.D., Corsini A., Vladutiu G.D., Raal F.J., Ray K.K., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur Heart J 2015, 36(17):1012-1022.
91. Fiala O., Pesek M., Finek J., Minarik M., Benesova L., Bortlicek Z., et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumour Biol 2015.
92. Selmi C. Hot topics in autoimmune diseases: perspectives from the 2013 Asian Congress of Autoimmunity. Autoimmun Rev 2014, 13:781-787.
93. Bartoloni E., Alunno A., Bistoni O., Gerli R. Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol 2013, 44:14-22.
94. Solomon D.H., Greenberg J., Curtis J.R., Liu M., Farkouh M.E., Tsao P., et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA): a CORRONA registry study. Arthritis Rheumatol 2015.
95. Kao A.H., Krishnaswami S., Cunningham A., Edmundowicz D., Morel P.A., Kuller L.H., et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol 2008, 35:61-69.
96. Arts E.E., Fransen J., den Broeder A.A., Popa C.D., Van Riel P.L. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2014, 74(6):998-1003.
97. Solomon D.H., Karlson E.W., Rimm E.B., Cannuscio C.C., Mandl L.A., Manson J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
98. Kaplan M.J. Cardiovascular complications of rheumatoid arthritis - assessment, prevention and treatment. Rheum Dis Clin N Am 2010, 36:405-426.
99. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
100. Pahau H., Brown M.A., Paul S., Thomas R., Videm V. Cardiovascular disease is increased prior to onset of rheumatoid arthritis but not osteoarthritis: the population-based Nord-Trondelag health study (HUNT). Arthritis Res Ther 2014, 16:R85.
101. Bartoloni E., Alunno A., Bistoni O., Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 2010, 9:701-707.
102. Franklin J., Farragher T.M., Lunt M., Camacho E.M., Bunn D., Marshall T., et al. Excess risk of hospital admission for cardiovascular disease within the first 7years from onset of inflammatory polyarthritis. Ann Rheum Dis 2010, 69:1660-1664.
103. Grundtman C., Hollan I., Forre O.T., Saatvedt K., Mikkelsen K., Lundberg I.E. Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum 2010, 62:667-673.
104. Maki-Petaja K.M., Elkhawad M., Cheriyan J., Joshi F.R., Ostor A.J., Hall F.C., et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012, 126:2473-2480.
105. Hollan I., Bottazzi B., Cuccovillo I., Forre O.T., Mikkelsen K., Saatvedt K., et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010, 62:378-385.
106. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
107. Ljung L., Jacobsson L.T., Rantapaa D.S., Askling J. Good response on tumour necrosis factor inhibitors are associated with a decreased risk of acute coronary syndromes in patients with rheumatoid arthritis [abstract] Abstract Number 805. Arthritis Rheum 2013, 65.
108. Ljung L., Askling J., Rantapaa-Dahlqvist S., Jacobsson L. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014, 16:R127.
109. Wasko M.C., Dasgupta A., Hubert H., Fries J.F., Ward M.M. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013, 65:334-342.
110. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:518-531.
111. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011, 63:522-529.
112. Micha R., Imamura F., Wyler von Ballmoos M., Solomon D.H., Hernan M.A., Ridker P.M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108:1362-1370.
113. Hsue P.Y., Scherzer R., Grunfeld C., Imboden J., Wu Y., Del Puerto G., et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 2014, 3:e001267.
114. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alen J., Horslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
115. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8:R151.
116. MacMullan P.A., Madigan A.M., Paul N., Peace A.J., Alagha A., Nolan K.B., et al. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2014.
117. Protogerou A.D., Zampeli E., Fragiadaki K., Stamatelopoulos K., Papamichael C., Sfikakis P.P. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011, 219:734-736.
118. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009, 30:2838-2844.
119. Wasko M.C., Hubert H.B., Lingala V.B., Elliott J.R., Luggen M.E., Fries J.F., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298:187-193.
120. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
121. Kotyla P.J., Owczarek A., Rakoczy J., Lewicki M., Kucharz E.J., Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol 2012, 39:701-706.
122. Myasoedova E., Crowson C.S., Nicola P.J., Maradit-Kremers H., Davis J.M., Roger V.L., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38:1601-1606.
123. Gullestad L., Ueland T., Vinge L.E., Finsen A., Yndestad A., Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012, 122:23-35.
124. Marks J.L., Edwards C.J. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012, 4:149-157.
125. Cacciapaglia F., Navarini L., Menna P., Salvatorelli E., Minotti G., Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 2011, 10:631-635.
126. Hjeltnes G., Hollan I., Forre O., Wiik A., Lyberg T., Mikkelsen K., et al. Endothelial function improves within 6weeks of treatment with methotrexate or methotrexate in combination with a TNF-alpha inhibitor in rheumatoid arthritis patients. Scand J Rheumatol 2012, 41:240-242.
127. Greco D., Favari E., Adorni M.P., Zimetti F., Gatti R., Bernini F., et al. Hydrocortisone directly promotes cholesterol accumulation in macrophages. Ann Rheum Dis 2014, 73:1274-1276.
128. Wallberg-Jonsson S., Johansson H., Ohman M.L., Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999, 26:2562-2571.
129. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732.
130. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770.
131. Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015, 74:480-489.
132. Listing J., Kekow J., Manger B., Burmester G.R., Pattloch D., Zink A., et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 2015, 74:415-421.
133. Avina-Zubieta J.A., Abrahamowicz M., De Vera M.A., Choi H.K., Sayre E.C., Rahman M.M., et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013, 52:68-75.
134. Del Rincón I., Battafarano D.F., Restrepo J.F., Erikson J.M., Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014, 66:264-272.
135. Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C.G., Leufkens H.G.M., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90:859-865.
136. Gremese E., Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011, 10:582-589.
137. Eurenius E., Stenstrom C.H. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 2005, 53:48-55.
138. Crowson C.S., Matteson E.L., Davis J.M., Gabriel S.E. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 2013, 65:71-77.
139. Del Rincón I., Freeman G.L., Haas R.W., O'Leary D.H., Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005, 52:3413-3423.
140. Saag K.G., Cerhan J.R., Kolluri S., Ohashi K., Hunninghake G.W., Schwartz D.A. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997, 56:463-469.
141. Stolt P., Bengtsson C., Nordmark B., Lindblad S., Lundberg I., Klareskog L., et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003, 62:835-841.
142. Evans M.R., Escalante A., Battafarano D.F., Freeman G.L., O'Leary D.H., del Rincon I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011, 63:1211-1220.
143. Karpouzas G.A., Malpeso J., Choi T.Y., Munoz S., Budoff M.J. Differential impact of cardiac risk factors on coronary plaque presence and features in asymptomatic patients with rheumatoid arthritis compared to controls. Ann Rheum Dis 2012, 64:1685.
144. McMaster W.G., Kirabo A., Madhur M.S., Harrison D.G. Inflammation, immunity, and hypertensive end-organ damage. Circ Res 2015, 116:1022-1033.
145. Cohen Tervaert J.W. Hypertension: an autoimmune disease?. Hypertens Res 2011, 34:443-444.
146. Hollan I., Scott H., Saatvedt K., Prayson R., Mikkelsen K., Nossent H.C., et al. Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 2007, 56:2072-2079.
147. Zhao Q., Hong D., Zhang Y., Sang Y., Yang Z., Zhang X. Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015, 94:e731.
148. Ben-Shlomo Y., Spears M., Boustred C., May M., Anderson S.G., Benjamin E.J., et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014, 63:636-646.
149. Giles J.T., Allison M., Blumenthal R.S., Post W., Gelber A.C., Petri M., et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010, 62:3173-3182.
150. Westhovens R., Nijs J., Taelman V., Dequeker J. Body composition in rheumatoid arthritis. Br J Rheumatol 1997, 36:444-448.
151. Santos M.J., Vinagre F., Canas da Silva J., Gil V., Fonseca J.E. Body composition phenotypes in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of Caucasian female patients. Clin Exp Rheumatol 2011, 29:470-476.
152. Elkan A.C., Engvall I.L., Cederholm T., Hafstrom I. Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques. Eur J Nutr 2009, 48:315-322.
153. Katz P.P., Yazdany J., Trupin L., Schmajuk G., Margaretten M., Barton J., et al. Sex differences in assessment of obesity in rheumatoid arthritis. Arthritis Care Res 2013, 65:62-70.
154. Uutela T., Kautiainen H., Jarvenpaa S., Salomaa S., Hakala M., Hakkinen A. Waist circumference based abdominal obesity may be helpful as a marker for unmet needs in patients with RA. Scand J Rheumatol 2014, 43:279-285.
155. Solomon A., Norton G.R., Woodiwiss A.J., Dessein P.H. Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2012, 14:R67.
156. Cerhan J.R., Moore S.C., Jacobs E.J., Kitahara C.M., Rosenberg P.S., Adami H.O., et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 2014, 89:335-345.
157. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
158. Kerekes G., Nurmohamed M.T., Gonzalez-Gay M.A., Seres I., Paragh G., Kardos Z., et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 2014, 10:691-696.
159. Engvall I.L., Elkan A.C., Tengstrand B., Cederholm T., Brismar K., Hafstrom I. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008, 37:321-328.
160. Rall L.C., Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004, 43:1219-1223.
161. Dessein P., Solomon A. Towards the elucidation of the true impact of adipocytokines on cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2013, 15:127.
162. Temiz A., Gokmen F., Gazi E., Akbal A., Barutcu A., Bekler A., et al. Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: associations in rheumatoid arthritis patients. Herz 2014, 40(Supplement 3):217-224.
163. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975, 58:243-264.
164. Shields K.J., Barinas-Mitchell E., Gingo M.R., Tepper P., Goodpaster B.H., Kao A.H., et al. Perivascular adipose tissue of the descending thoracic aorta is associated with systemic lupus erythematosus and vascular calcification in women. Atherosclerosis 2013, 231:129-135.
165. Kremers H.M., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004, 50:3450-3457.
166. Escalante A., Haas R.W., Del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005, 165:1624-1629.
167. Romero-Corral A., Montori V.M., Somers V.K., Korinek J., Thomas R.J., Allison T.G., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006, 368:666-678.
168. Azimi A., Charlot M.G., Torp-Pedersen C., Gislason G.H., Kober L., Jensen L.O., et al. Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart 2013, 99:655-660.
169. Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J., Treharne G.J., Panoulas V.F., Douglas K.M., et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) 2008, 47:239-248.
170. Janse van Rensburg D.C., Ker J.A., Grant C.C., Fletcher L. Effect of exercise on cardiac autonomic function in females with rheumatoid arthritis. Clin Rheumatol 2012, 31:1155-1162.
171. Turesson C., Matteson E.L. Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 2007, 19:190-196.
172. Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J., Nightingale P., Sandoo A., Dimitroulas T., et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014, 73:748-751.
173. Stavropoulos-Kalinoglou A., Metsios G.S., Veldhuijzen van Zanten J.J., Nightingale P., Kitas G.D., Koutedakis Y. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72:1819-1825.
174. Colbert L.H., Visser M., Simonsick E.M., Tracy R.P., Newman A.B., Kritchevsky S.B., et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004, 52:1098-1104.
175. Kasapis C., Thompson P.D. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005, 45:1563-1569.
176. Sandberg M.E., Wedren S., Klareskog L., Lundberg I.E., Opava C.H., Alfredsson L., et al. Patients with regular physical activity before onset of rheumatoid arthritis present with milder disease. Ann Rheum Dis 2014, 73:1541-1544.
177. Raschke S., Eckel J. Adipo-myokines: two sides of the same coin-mediators of inflammation and mediators of exercise. Mediat Inflamm 2013, 2013:320724.
178. Kim J.S., Kim B., Lee H., Thakkar S., Babbitt D.M., Eguchi S., et al. Shear stress-induced mitochondrial biogenesis decreases the release of microparticles from endothelial cells. Am J Physiol Heart Circ Physiol 2015, [ajpheart 00438 2014].
179. Pan S. Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress. Antioxid Redox Signal 2009, 11:1669-1682.
180. Solomon A., Woodiwiss A.J., Abdool-Carrim A.T., Stevens B.A., Norton G.R., Dessein P.H. The carotid artery atherosclerosis burden and its relation to cardiovascular risk factors in black and white Africans with established rheumatoid arthritis: a cross-sectional study. J Rheumatol 2012, 39:1798-1806.
181. Margaretten M., Julian L., Katz P., Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 2011, 6:617-623.
182. Lichtman J.H., Bigger J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lesperance F., et al. AHA science advisory. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee to the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care Outcomes Research. Endorsed by the American Psychiatric Association. Prog Cardiovasc Nurs 2009, 24:19-26.
183. Reading S.R., Crowson C.S., Rodeheffer R.J., Fitz-Gibbon P.D., Maradit-Kremers H., Gabriel S.E. Do rheumatoid arthritis patients have a higher risk for sleep apnea?. J Rheumatol 2009, 36:1869-1872.
184. Taylor-Gjevre R.M., Gjevre J.A., Nair B.V., Skomro R.P., Lim H.J. Improved sleep efficiency after anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients. Ther Adv Musculoskelet Dis 2011, 3:227-233.
185. Drossaers-Bakker K.W., Hamburger H.L., Bongartz E.B., Dijkmans B.A., Van Soesbergen R.M. Sleep apnoea caused by rheumatoid arthritis. Br J Rheumatol 1998, 37:889-894.
186. Marshall N.S., Wong K.K.H., Liu P.Y., Cullen S.R.J., Knuiman M.W., Grunstein R.R. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008, 31:1079-1085.
187. Kulkas A. Morbidity and mortality risk ratios are elevated in severe supine dominant OSA: a long-term follow-up study 2014.
188. Kang J.H., Lin H.C. Obstructive sleep apnea and the risk of autoimmune diseases: a longitudinal population-based study. Sleep Med 2012, 13:583-588.
189. McNicholas W.T. Obstructive sleep apnea and inflammation. Prog Cardiovasc Dis 2009, 51:392-399.
190. Walsh J.A., Duffin K.C., Crim J., Clegg D.O. Lower frequency of obstructive sleep apnea in spondyloarthritis patients taking TNF-inhibitors. J Clin Sleep Med 2012, 8:643-648.
191. Lee Y.L., Hu H.Y., Chou P., Chu D. Dental prophylaxis decreases the risk of acute myocardial infarction: a nationwide population-based study in Taiwan. Clin Interv Aging 2015, 10:175-182.
192. Reichert S., Schlitt A., Beschow V., Lutze A., Lischewski S., Seifert T., et al. Use of floss/interdental brushes is associated with lower risk for new cardiovascular events among patients with coronary heart disease. J Periodontal Res 2014, 50(2):180-188.
193. Frisbee S.J., Chambers C.B., Frisbee J.C., Goodwill A.G., Crout R.J. Association between dental hygiene, cardiovascular disease risk factors and systemic inflammation in rural adults. J Dent Hyg 2010, 84:177-184.
194. de Oliveira C., Watt R., Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. BMJ 2010, 340:c2451.
195. Uyar I.S., Sahin V., Akpinar M.B., Abacilar F., Okur F.F., Ozdemir U., et al. Does oral hygiene trigger carotid artery intima-media thickness?. Heart Surg Forum 2013, 16:E232-E236.
196. Udell J.A., Zawi R., Bhatt D.L., Keshtkar-Jahromi M., Gaughran F., Phrommintikul A., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013, 310:1711-1720.
197. Vlachopoulos C.V., Terentes-Printzios D.G., Aznaouridis K.A., Pietri P.G., Stefanadis C.I. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol 2014.
198. Pludowski P., Holick M.F., Pilz S., Wagner C.L., Hollis B.W., Grant W.B., et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013, 12:976-989.
199. Zheng Z., Shi H., Jia J., Li D., Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 2013, 14:199.
200. Dessein P.H. Vitamin D, replacement therapy: a promising adjunct in cardiovascular risk management among patients with rheumatoid arthritis?. J Rheumatol 2013, 40:1463-1465.
201. Danik J.S., Manson J.E. Vitamin D and cardiovascular disease. Curr Treat Options Cardiovasc Med 2012, 14:414-424.
202. Bjelakovic G., Gluud L.L., Nikolova D., Whitfield K., Wetterslev J., Simonetti R.G., et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014, 1:Cd007470.
203. Pludowski P., Karczmarewicz E., Bayer M., Carter G., Chlebna-Sokol D., Czech-Kowalska J., et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol 2013, 64:319-327.
204. Durup D., Jørgensen H.L., Christensen J., Tjønneland A., Olsen A., Halkjær J., et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality - the CopD-study. J Clin Endocrinol Metab 2015, 100(6):2339-2346.
205. Raterman H.G., van Halm V.P., Voskuyl A.E., Simsek S., Dijkmans B.A.C., Nurmohamed M.T. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. Ann Rheum Dis 2008, 67:229-232.
206. Rodondi N., den Elzen W.P., Bauer D.C., Cappola A.R., Razvi S., Walsh J.P., et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010, 304:1365-1374.
207. Lu M., Yang C.B., Gao L., Zhao J.J. Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review). Exp Ther Med 2015, 9:3-10.
208. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435-442.
209. Panoulas V.F., Milionis H.J., Douglas K.M., Nightingale P., Kita M.D., Klocke R., et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1466-1470.
210. Meek I.L., Vonkeman H.E., van de Laar M.A. Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord 2014, 15:142.
211. Kuo D., Crowson C.S., Gabriel S.E., Matteson E.L. Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol 2014, 2014:523897.
212. Becker M.A. Asymptomatic hyperuricemia 2015.
213. Akhavani M.A., Larsen H., Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand J Rheumatol 2007, 36:83-90.
214. Park Y.J., Kim J.Y., Park J., Choi J.J., Kim W.U., Cho C.S. Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis. Arthritis Rheumatol 2014, 66:1450-1460.
215. Jodon de Villeroche V., Avouac J., Ponceau A., Ruiz B., Kahan A., Boileau C., et al. Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. Arthritis Res Ther 2010, 12:R27.
216. Lee P.S.S., Poh K.K. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells 2014, 6:355-366.
217. Wu S.Y., Mayneris-Perxachs J., Lovegrove J.A., Todd S., Yaqoob P. Fish-oil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independently of eNOS genotype. Am J Clin Nutr 2014, 100:1232-1243.
218. de Souza A.W., Westra J., Limburg P.C., Bijl M., Kallenberg C.G. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012, 11:909-917.
219. Harris H.E., Andersson U., Pisetsky D.S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8:195-202.
220. Hollan I., Zong M., Grundtman C., Lindroos E., Harris H.E., Mikkelsen K., et al. Expression of high mobility group protein B1 and its receptors in heart of patients with coronary artery disease with and without inflammatory rheumatic disease: a biopsy study. Autoimmun Congr 2014, [abstract from the autoimmunity congress 2014].
221. Clarke G., Stilling R.M., Kennedy P.J., Stanton C., Cryan J.F., Dinan T.G. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol 2014, 28:1221-1238.
222. Manco M., Putignani L., Bottazzo G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010, 31:817-844.
223. Geurts L., Neyrinck A.M., Delzenne N.M., Knauf C., Cani P.D. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benefic Microbes 2014, 5:3-17.
224. McLean M.H., Dieguez D., Miller L.M., Young H.A. Does the microbiota play a role in the pathogenesis of autoimmune diseases?. Gut 2015, 64(2):332-341.
225. Juneau M., Hayami D., Gayda M., Lacroix S., Nigam A. Provocative issues in heart disease prevention. Can J Cardiol 2014, 30:S401-S409.
226. Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. Autoimmun Rev 2014, 13:331-346.
227. Lindhardsen J., Gislason G.H., Jacobsen S., Ahlehoff O., Olsen A.M., Madsen O.R., et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014, 73:1515-1521.
228. Goodson N.J., Brookhart A.M., Symmons D.P., Silman A.J., Solomon D.H. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009, 68:367-372.
229. Roberts E., Delgado Nunes V., Buckner S., Latchem S., Constanti M., Miller P., et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2015.
230. Curran S.A., Hollan I., Erridge C., Lappin D.F., Murray C.A., Sturfelt G., et al. Bacteria in the adventitia of cardiovascular disease patients with and without rheumatoid arthritis. PLoS One 2014, 9:e98627.
231. Hollan I., Hjeltnes G., Lyberg T., Agewall S., Wiik A., Mikkelsen K., et al. Anti-rheumatic therapy decreases syndecan-1 shedding in rheumatoid arthritis (RA). ACR 2014 2014.
232. Khandpur R., Carmona-Rivera C., Vivekanandan-Giri A., Gizinski A., Yalavarthi S., Knight J.S., et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013, 5:178ra40.
233. Doring Y., Soehnlein O., Weber C. Neutrophils cast NETs in atherosclerosis: employing peptidylarginine deiminase as a therapeutic target. Circ Res 2014, 114:931-934.
234. Carmona-Rivera C., Zhao W., Yalavarthi S., Kaplan M.J. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis 2015, 74(7):1417-1424.
235. John H., Carroll D., Kitas G.D. Cardiovascular education for people with rheumatoid arthritis: what can existing patient education programmes teach us?. Rheumatology (Oxford) 2011, 50:1751-1759.
236. Task Force M., Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013, 34:2949-3003.
237. Authors/Task Force m, Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35:2541-2619.
238. Pharmacotherapy for smoking cessation in adults 2015.
239. Bao Y., Han J., Hu F.B., Giovannucci E.L., Stampfer M.J., Willett W.C., et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med 2013, 369:2001-2011.
240. Proudman S.M., James M.J., Spargo L.D., Metcalf R.G., Sullivan T.R., Rischmueller M., et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 2015, 74:89-95.
241. Eilat-Adar S., Sinai T., Yosefy C., Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013, 5:3646-3683.
242. Prasad S., Gupta S.C., Tyagi A.K., Aggarwal B.B. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 2014, 32:1053-1064.
243. Ramadan G., El-Menshawy O. Protective effects of ginger-turmeric rhizomes mixture on joint inflammation, atherogenesis, kidney dysfunction and other complications in a rat model of human rheumatoid arthritis. Int J Rheum Dis 2013, 16:219-229.
244. Tanasescu M., Leitzmann M.F., Rimm E.B., Willett W.C., Stampfer M.J., Hu F.B. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002, 288:1994-2000.
245. Lee D.C., Pate R.R., Lavie C.J., Sui X., Church T.S., Blair S.N. Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol 2014, 64:472-481.
246. Wang C. Role of Tai Chi in the treatment of rheumatologic diseases. Curr Rheumatol Rep 2012, 14:598-603.
247. Ross A., Thomas S. The health benefits of yoga and exercise: a review of comparison studies. J Altern Complement Med 2010, 16:3-12.
248. Black D.S., Cole S.W., Irwin M.R., Breen E., St Cyr N.M., Nazarian N., et al. Yogic meditation reverses NF-kappaB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. Psychoneuroendocrinology 2013, 38:348-355.
249. Badsha H., Chhabra V., Leibman C., Mofti A., Kong K.O. The benefits of yoga for rheumatoid arthritis: results of a preliminary, structured 8-week program. Rheumatol Int 2009, 29:1417-1421.
250. Telles S., Naveen K.V., Gaur V., Balkrishna A. Effect of one week of yoga on function and severity in rheumatoid arthritis. BMC Res Notes 2011, 4:118.
251. Cleland L.G., Caughey G.E., James M.J., Proudman S.M. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol 2006, 33:1973-1979.
252. Dessein P.H., Joffe B.I. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:161-167.
253. Makrygiannakis D., Revu S., Engstrom M., Af Klint E., Nicholas A.P., Pruijn G.J., et al. Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis. Arthritis Res Ther 2012, 14:R20.
254. Konai M.S., Vilar Furtado R.N., Dos Santos M.F., Natour J. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol 2009, 27:214-221.
255. Furtado R.N., Oliveira L.M., Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005, 32:1691-1698.
256. Rothwell P.M., Price J.F., Fowkes F.G., Zanchetti A., Roncaglioni M.C., Tognoni G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612.
257. Tournadre A., Tatar Z., Pereira B., Chevreau M., Gossec L., Gaudin P., et al. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. Int J Cardiol 2015, 183:149-154.